David Hui, MD
Disclosures: Paid consultant-Eton Pharmaceuticals - 03/26/2022

David Hui, MD, MSc, FAAHPM

[email protected]


Dr. David Hui is a tenured associate professor at the Department of Palliative Care, Rehabilitation and Integrative Medicine, with a joint appointment to the Department of General Oncology at the University of Texas MD Anderson Cancer Center, Houston, USA. His research interests include integration of supportive/palliative care and oncology, symptom management clinical trials, prognostication, and research methodology. He completed his medical school at the University of British Columbia, Vancouver, Canada, followed by internal medicine residency at the University of Alberta, Edmonton, medical oncology fellowship at the British Columbia Cancer Agency, and supportive/palliative oncology clinical research fellowship at the University of Texas MD Anderson Cancer Center.  He also has a Master’s degree in Biochemistry and Molecular Biology, and a second Master’s degree in Patient Based Biological Research.  He is board certified in Internal Medicine and Medical Oncology in Canada and the US, and also Palliative Care and Hospice Medicine in the US.


He is currently the principal investigator of multiple randomized trials on dyspnea and delirium funded by the National Cancer Institute. His research is also supported by the National Institute of Nursing Research, the American Cancer Society and other agencies. He has authored and/or co-authored over 300 scientific papers, with his work appearing at various peer-review journals such as JAMA, JAMA Oncol, J Clin Oncol, CA: A Cancer Journal for Clinicians, Lancet Oncol and Ann Oncol. He is also the author/editor of 4 books (Approach to Internal Medicine, Drugs & Drugs, and Internal Medicine Issues in Palliative Cancer Care, 50 Palliative Care Studies Every Doctor Should Know).


Dr. Hui currently serves as a permanent member of a study section at the National Institutes of Health. He is also a senior associate editor of the Journal of Pain and Symptom Management. In addition to academic pursuits, he remains active clinically in both palliative care and medical oncology.